mevalonic acid has been researched along with Bright Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Christensen, M; Greco, A; Lipschutz, JH; Madaio, MP; Snyder, RW; Su, AW | 1 |
| Guijarro, C; Keane, WF | 1 |
1 review(s) available for mevalonic acid and Bright Disease
| Article | Year |
|---|---|
Effects of lipids on the pathogenesis of progressive renal failure: role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in the prevention of glomerulosclerosis.
Topics: Animals; Anticholesteremic Agents; Cell Division; Collagen; Colony-Stimulating Factors; Extracellular Matrix Proteins; Gene Expression; Glomerular Mesangium; Glomerulonephritis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Kidney; Kidney Failure, Chronic; Lovastatin; Mevalonic Acid | 1996 |
1 other study(ies) available for mevalonic acid and Bright Disease
| Article | Year |
|---|---|
Simvastatin protection against acute immune-mediated glomerulonephritis in mice.
Topics: Acute Disease; Animals; Blood Urea Nitrogen; Disease Progression; Dose-Response Relationship, Drug; Female; Glomerulonephritis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Mevalonic Acid; Mice; Mice, Inbred C57BL; Proteinuria; Severity of Illness Index; Simvastatin | 2006 |